Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Licenses Stanford Biomarker Panel for Peripheral Artery Disease

NEW YORK (GenomeWeb News) — Vermillion has licensed a biomarker panel from Stanford University that could be used to assess the risk of peripheral artery disease, the company said today.
 
The agreement gives Vermillion exclusive rights to develop and commercialize a blood-based PAD test, which would use the multi-marker panel to stratify individual risk for developing the disease.
 
The company said PAD, which can result in complications such as gangrene, heart attack, stroke, and death, may affect as many as 12 million Americans.
 
The agreement builds on an existing collaboration between Vermillion (formerly called Ciphergen) and Stanford on PAD biomarker development. Last January, Ciphergen said it had signed an agreement with Quest to develop a blood-based test for the disease through a partnership with the university.
 
Vermillion, based in Fremont, Calif., said today that it also worked with Stanford to conduct a 540-patient, collaborative clinical evaluation study of the biomarker panel to classify individuals into high- and low-risk groups for PAD.
 
The company said the results of the study will be published in a peer-reviewed clinical journal “in the coming months.”
 
Financial terms of the biomarker licensing agreement were not released.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.